Literature DB >> 15979460

Midkine, a newly discovered regulator of the renin-angiotensin pathway in mouse aorta: significance of the pleiotrophin/midkine developmental gene family in angiotensin II signaling.

Laura Ezquerra1, Gonzalo Herradon, Trang Nguyen, Inmaculada Silos-Santiago, Thomas F Deuel.   

Abstract

We previously demonstrated that pleiotrophin (PTN the protein, Ptn the gene) highly regulates the levels of expression of the genes encoding the proteins of the renin-angiotensin pathway in mouse aorta. We now demonstrate that the levels of expression of these same genes are significantly regulated in mouse aorta by the PTN family member midkine (MK the protein, Mk the gene); a 3-fold increase in expression of renin, an 82-fold increase in angiotensinogen, a 6-fold decrease in the angiotensin converting enzyme, and a 6.5-fold increase in the angiotensin II type 1 and a 9-fold increase in the angiotensin II type 2 receptor mRNAs were found in Mk-/- mouse aorta in comparison with the wild type (WT, +/+). The results in Mk-/- mice are remarkably similar to those previously reported in Ptn-/- mouse aorta, with the single exception of that the levels of the angiotensinogen gene expression in Ptn-/- mice are equal to those in WT+/+ mouse aorta, and thus, in contrast to Mk gene expression unaffected by levels of Ptn gene expression. The data indicate that MK and PTN share striking but not complete functional redundancy. These data support potentially high levels importance of MK and the MK/PTN developmental gene family in downstream signals initiated by angiotensin II either in development or in the many pathological conditions in which MK expression levels are increased, such as atherosclerosis and many human neoplasms that acquire constitutive endogenous Mk gene expression by mutation during tumor progression and potentially provide a target through the renin-angiotensin pathway to treat advanced malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979460     DOI: 10.1016/j.bbrc.2005.05.113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1.

Authors:  Delia Lidia Şalaru; Peter R Mertens; Peter Bartsch
Journal:  Int Urol Nephrol       Date:  2013-03-30       Impact factor: 2.370

Review 3.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  The growth factor midkine regulates the renin-angiotensin system in mice.

Authors:  Akinori Hobo; Yukio Yuzawa; Tomoki Kosugi; Noritoshi Kato; Naoto Asai; Waichi Sato; Shoichi Maruyama; Yasuhiko Ito; Hiroyuki Kobori; Shinya Ikematsu; Akira Nishiyama; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

Review 5.  Midkine in nephrogenesis, hypertension and kidney diseases.

Authors:  Waichi Sato; Yuka Sato
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 6.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 7.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 8.  Physiology of Midkine and Its Potential Pathophysiological Role in COVID-19.

Authors:  Giulia Sanino; Martino Bosco; Giuseppe Terrazzano
Journal:  Front Physiol       Date:  2020-12-22       Impact factor: 4.566

9.  Midkine release during hemodialysis is predictive of hypervolemia and associates with excess (cardiovascular) mortality in patients with end-stage renal disease: a prospective study.

Authors:  Sabine Brandt; Anja Fischer; Carla Kreutze; Dorothea Hempel; Xenia Gorny; Florian G Scurt; Delia L Şalaru; Peter Bartsch; Anja Bernhardt; Stefanie M Bode-Böger; Matthias Girndt; Roman Fiedler; Berend Isermann; Jonathan A Lindquist; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2022-02-24       Impact factor: 2.266

10.  Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer.

Authors:  Huifang Hao; Yutaka Maeda; Takuya Fukazawa; Tomoki Yamatsuji; Munenori Takaoka; Xiao-Hong Bao; Junji Matsuoka; Tatsuo Okui; Tsuyoshi Shimo; Nagio Takigawa; Yasuko Tomono; Motowo Nakajima; Iris M Fink-Baldauf; Sandra Nelson; William Seibel; Ruben Papoian; Jeffrey A Whitsett; Yoshio Naomoto
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.